Ariston Pharma Nova Tech Private Limited - Due diligence report

A 360° intelligence report on Aristonpharmanovatech: trust score, financial health, credit view, compliance, directors, growth and distress …

2012-10-19 Hyderabad, Telangana Under Liquidation Unlisted Active Compliant
Share
AP Ariston Pharma Nova Tech Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Aristonpharmanovatech — 360° Intelligence Report

Generated from MCA filings & public records
52/100
Trust Score
Moderate

Aristonpharmanovatech is assessed as Moderate with a Trust Score of 52/100. Aristonpharmanovatech is a private limited indian non-government company incorporated in 2012, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and moderate financial risk profile.

Report generated on 16 Jul 2026 from the latest processed filings. Ariston Pharma Nova Tech Private Limited snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Neutral
Compliance › Caution

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
52/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
5/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
65/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
40/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Profitable - internal accruals available.

Charges position: 2 open (6.09 cr) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Syndicate Bank2 48.0 cr
Compliance Score: 5/100 Caution Indicated
  • Company status is "Under Liquidation" - not Active.
  • Last balance sheet is for Mar 2019 - filings overdue.
  • Flagged by authority: EPFO.
  • Litigation present in 2 court forum(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
VEDPRAKASH VYAS 01234567 Director 01/04/2018 6 yrs Approved
Rajesh Chillale 01234567 Director 01/04/2018 6 yrs Approved
SUBHASH GOVERDHANDASJI BISSA 01234567 Director 01/04/2018 6 yrs Approved
SHANKAR SHARMA 01234567 Director 01/04/2018 6 yrs Approved
Rounak Sharma 01234567 Director 01/04/2018 6 yrs Approved
  • 5 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2017)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2019 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
12 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 70 · Distress 40
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Operating for 13+ years.
Active EPFO - real payroll on record.
Distress signals & risk flags
Revenue declined year-on-year.
Statutory filings appear overdue.
Adverse company status: Under Liquidation.
Compliance score is weak (5/100).
2 open charge(s) registered - assets are encumbered.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence30/100
Caution indicated
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 3 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment39/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 2 open charge(s) of 6.09 cr already registered.
  • Compliance gaps should be priced into terms.
Investor view64/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
16 Oct 2024
Director appointed
SHANKAR SHARMA (Director)
Director appointed
Rounak Sharma (Director)
24 May 2024
Director appointed
Rajesh Chillale (IRP/RP/Liquidator)
30 Sep 2019
Director ceased
SUBHASH GOVERDHANDASJI BISSA
Last AGM held
Annual general meeting
25 Sep 2019
Director appointed
SUBHASH GOVERDHANDASJI BISSA (Director)
Director ceased
JYOTHI VYAS
31 Mar 2019
Latest balance sheet
Filed with ROC
08 Aug 2018
Securities allotted
8990 Equity Shares Without Differential Rights - 44.95 Lakh raised
20 Mar 2018
Securities allotted
8990 Equity Shares Without Differential Rights - 44.95 Lakh raised
27 Nov 2017
Securities allotted
800 Equity Shares Without Differential Rights - 4.00 Lakh raised
Securities allotted
19200 Equity Shares Without Differential Rights - 96.00 Lakh raised
28 Sep 2017
Securities allotted
800 Equity Shares Without Differential Rights - 4.00 Lakh raised
20 Sep 2017
Director ceased
ALGATOORI BHAVANI
30 Jul 2017
Securities allotted
19200 Equity Shares Without Differential Rights - 96.00 Lakh raised
10

Key Observations

Auto-generated from the data above
Revenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Debt-to-equity stands at 61% - leverage worth monitoring.
Net worth is positive.
5 active director(s) / partner(s); board looks stable and experienced.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2019 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 12 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
G T Pest Control Private Limited U74900PN2009PTC134609 Pune, Maharashtra, India
'10 Days' Hair Oil U74999TZ2017PTC029317 Coimbatore, Tamil Nadu, India
Sivasakthi Industrial Explosives Private Limited U24292TZ2008PTC014580 Salem, Tamil Nadu, India
Vilin Bio Med Limited L24230TG2005PLC046689 Khairatabad, Telangana, India
Raffles Green Pet India Private Limited U37200GJ2013PTC076748 Kheda, Gujarat, India
Piramal Phytocare Limited L73100MH2001PLC132523 Mumbai, Maharashtra, India
Surfactant Products Private Limited U24100GJ2012PTC071130 Ahmedabad, Gujarat, India
Strides U24290MH2003PTC138910 Mumbai, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Aristonpharmanovatech before audits and certifications: compliance score 5/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Aristonpharmanovatech: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Enhanced diligence advised. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 70/100, margin trends, ownership structure and peer set for Aristonpharmanovatech - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Caution indicated. Trust score 52/100, distress signals and MSME payment-delay disclosures - know whether Aristonpharmanovatech pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Aristonpharmanovatech - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Aristonpharmanovatech an active company?

Aristonpharmanovatech has MCA status “Under Liquidation” with a compliance score of 5/100 (Caution Indicated).

Is Aristonpharmanovatech financially healthy?

Aristonpharmanovatech has a Financial Health Score of 65/100 (Moderate) based on its filed financial statements.

Should I do business with Aristonpharmanovatech?

Its overall Trust Score is 52/100 (Moderate). Vendor verdict: Caution indicated. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Aristonpharmanovatech?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 5 active director(s) are on record.

Does Aristonpharmanovatech have loans or charges against its assets?

2 open charge(s) are registered against its assets.

Is Aristonpharmanovatech up to date with its ROC filings?

Last balance sheet is for Mar 2019 - filings overdue. Overall compliance score: 5/100 (Caution Indicated).

Is it risky to lend to Aristonpharmanovatech?

Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.